251 related articles for article (PubMed ID: 20361312)
21. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
22. Impaired osteoclastogenesis by staphylococcal lipoteichoic acid through Toll-like receptor 2 with partial involvement of MyD88.
Yang J; Ryu YH; Yun CH; Han SH
J Leukoc Biol; 2009 Oct; 86(4):823-31. PubMed ID: 19602669
[TBL] [Abstract][Full Text] [Related]
23. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway.
Lee MS; Kim HS; Yeon JT; Choi SW; Chun CH; Kwak HB; Oh J
J Immunol; 2009 Sep; 183(5):3390-9. PubMed ID: 19641137
[TBL] [Abstract][Full Text] [Related]
24. Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells.
Kharkwal G; Chandra V; Fatima I; Dwivedi A
J Mol Endocrinol; 2012 Jun; 48(3):261-70. PubMed ID: 22493142
[TBL] [Abstract][Full Text] [Related]
25. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
[TBL] [Abstract][Full Text] [Related]
26. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
27. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
28. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
30. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
31. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
32. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
[TBL] [Abstract][Full Text] [Related]
33. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
Shim KS; Ma CJ; Kim DS; Ma JY
J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
[TBL] [Abstract][Full Text] [Related]
34. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
Tsuji-Naito K
Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
[TBL] [Abstract][Full Text] [Related]
35. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
Park EK; Kim MS; Lee SH; Kim KH; Park JY; Kim TH; Lee IS; Woo JT; Jung JC; Shin HI; Choi JY; Kim SY
Biochem Biophys Res Commun; 2004 Dec; 325(4):1472-80. PubMed ID: 15555594
[TBL] [Abstract][Full Text] [Related]
36. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
[TBL] [Abstract][Full Text] [Related]
39. Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK.
Ang E; Liu Q; Qi M; Liu HG; Yang X; Chen H; Zheng MH; Xu J
J Cell Biochem; 2011 Jan; 112(1):89-97. PubMed ID: 20683903
[TBL] [Abstract][Full Text] [Related]
40. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
Huang H; Chang EJ; Ryu J; Lee ZH; Lee Y; Kim HH
Biochem Biophys Res Commun; 2006 Dec; 351(1):99-105. PubMed ID: 17052691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]